{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:11:38Z","timestamp":1760616698700,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.rmed.2019.01.015","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T11:33:35Z","timestamp":1549020815000},"page":"23-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The development of sarcoidosis in patients receiving daclizumab: A case series from multiple clinical trials"],"prefix":"10.1016","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4663-7985","authenticated-orcid":false,"given":"Marc A.","family":"Judson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett M.","family":"Elicker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas V.","family":"Colby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sooyeon","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"de Windt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyros","family":"Chalkias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Prada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Smirnakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.rmed.2019.01.015_bib1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.chest.2018.03.056","article-title":"Drug-induced sarcoidosis-like reactions","volume":"154","author":"Chopra","year":"2018","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.rmed.2019.01.015_bib2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/1756285615605429","article-title":"Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes","volume":"8","author":"Lycke","year":"2015","journal-title":"Therapeutic advances in neurological disorders"},{"issue":"21","key":"10.1016\/j.rmed.2019.01.015_bib3","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1212\/WNL.0b013e318239f7ef","article-title":"Intrathecal effects of daclizumab treatment of multiple sclerosis","volume":"77","author":"Bielekova","year":"2011","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/j.rmed.2019.01.015_bib4","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1501481","article-title":"Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis","volume":"373","author":"Kappos","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2019.01.015_bib5","first-page":"19","article-title":"The WASOG Sarcoidosis Organ Assessment Instrument: an update of a previous clinical tool","volume":"31","author":"Judson","year":"2014","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"8","key":"10.1016\/j.rmed.2019.01.015_bib6","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1513\/AnnalsATS.201511-760OC","article-title":"Sarcoidosis in America. Analysis based on health care use","volume":"13","author":"Baughman","year":"2016","journal-title":"Annals of the American Thoracic Society"},{"issue":"1","key":"10.1016\/j.rmed.2019.01.015_bib7","first-page":"29","article-title":"Sarcoidosis and multiple sclerosis: systemic toxicity associated with the use of interferon-beta therapy","volume":"77","author":"Carbonelli","year":"2012","journal-title":"Monaldi Arch. Chest Dis."},{"key":"10.1016\/j.rmed.2019.01.015_bib8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/1752-1947-6-344","article-title":"Interferon-beta-induced pulmonary sarcoidosis in a 30-year-old woman treated for multiple sclerosis: a case report","volume":"6","author":"Petousi","year":"2012","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.rmed.2019.01.015_bib9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/1752-1947-7-270","article-title":"Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with interferon-beta-1b: a case report","volume":"7","author":"Sahraian","year":"2013","journal-title":"J. Med. Case Rep."},{"issue":"4","key":"10.1016\/j.rmed.2019.01.015_bib10","first-page":"316","article-title":"Activated CD8+ T cells and natural killer T cells in bronchoalveolar lavage fluid in hypersensitivity pneumonitis and sarcoidosis","volume":"31","author":"Tondell","year":"2015","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"8","key":"10.1016\/j.rmed.2019.01.015_bib11","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/eji.201243185","article-title":"Invariant natural killer T (iNKT) cell exhaustion in sarcoidosis","volume":"43","author":"Snyder-Cappione","year":"2013","journal-title":"Eur. J. Immunol."},{"issue":"9","key":"10.1016\/j.rmed.2019.01.015_bib12","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","article-title":"A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors","volume":"26","author":"Chen","year":"2015","journal-title":"Ann. Oncol.: official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.rmed.2019.01.015_bib13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1\/anti-Programmed cell Death-Ligand 1 agents: a single-centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.rmed.2019.01.015_bib14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2019.01.015_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.msard.2017.12.011","article-title":"Pulmonary sarcoidosis in a patient with multiple sclerosis on daclizumab monotherapy","volume":"20","author":"Rhone","year":"2018","journal-title":"Multiple sclerosis and related disorders"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611119300319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611119300319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:42:39Z","timestamp":1760614959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611119300319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":15,"alternative-id":["S0954611119300319"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2019.01.015","relation":{},"ISSN":["0954-6111"],"issn-type":[{"type":"print","value":"0954-6111"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The development of sarcoidosis in patients receiving daclizumab: A case series from multiple clinical trials","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2019.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}